Findings

What do systematic reviews say?

44 questions · 44 findings · 23 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 9.1%GRADE not reported 3 · 6.8%Very low 12 · 27.3%Low 12 · 27.3%Moderate 9 · 20.5%High 4 · 9.1%

Intervention not reported

Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
51 studies · 162422 participants
Very low

Intervention not reported

Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
49 studies · 13978 participants
Very low

Intervention not reported

Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)

It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).

1 finding from 1 review

Corticosteroids for preventing postherpetic neuralgia 2023 · Cochrane Headline outcomes only
RR 1.65 [0.51, 5.29]
5 studies · 755 participants
Very low

Intervention not reported

Non‐serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)

The intervention showed no clear difference in non‐serious adverse eventsClinical manifestation and laboratory… (low certainty).

1 finding from 1 review

Corticosteroids for preventing postherpetic neuralgia 2023 · Cochrane Headline outcomes only
RR 1.3 [0.9, 1.87]
5 studies · 755 participants
Low